Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 180.76 Billion KRW | 11.11% |
| 2022 | 162.69 Billion KRW | 16.37% |
| 2021 | 139.8 Billion KRW | 5.14% |
| 2020 | 132.96 Billion KRW | -1.25% |
| 2019 | 134.64 Billion KRW | 2.95% |
| 2018 | 130.79 Billion KRW | 0.24% |
| 2017 | 130.48 Billion KRW | 8.71% |
| 2016 | 120.02 Billion KRW | 9.28% |
| 2015 | 109.82 Billion KRW | 1.85% |
| 2014 | 107.83 Billion KRW | -0.28% |
| 2013 | 108.13 Billion KRW | 5.75% |
| 2012 | 102.25 Billion KRW | -9.55% |
| 2011 | 113.04 Billion KRW | 1.06% |
| 2010 | 111.86 Billion KRW | -8.97% |
| 2009 | 122.87 Billion KRW | 1.96% |
| 2008 | 120.52 Billion KRW | 7.93% |
| 2007 | 111.66 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 43.88 Billion KRW | 2.59% |
| 2024 Q3 | 46.22 Billion KRW | 5.33% |
| 2024 Q1 | 42.77 Billion KRW | -6.14% |
| 2023 Q3 | 47.44 Billion KRW | -2.88% |
| 2023 Q2 | 48.85 Billion KRW | 25.61% |
| 2023 Q1 | 38.89 Billion KRW | -5.5% |
| 2023 Q4 | 45.56 Billion KRW | -3.95% |
| 2023 FY | 180.76 Billion KRW | 11.11% |
| 2022 Q3 | 42.85 Billion KRW | 3.95% |
| 2022 FY | 162.69 Billion KRW | 16.37% |
| 2022 Q4 | 41.15 Billion KRW | -3.95% |
| 2022 Q2 | 41.22 Billion KRW | 10.08% |
| 2022 Q1 | 37.45 Billion KRW | 10.79% |
| 2021 Q2 | 37.3 Billion KRW | 22.62% |
| 2021 Q3 | 38.27 Billion KRW | 2.62% |
| 2021 Q1 | 30.42 Billion KRW | -8.57% |
| 2021 FY | 139.8 Billion KRW | 5.14% |
| 2021 Q4 | 33.8 Billion KRW | -11.69% |
| 2020 Q1 | 32.13 Billion KRW | 1.7% |
| 2020 Q4 | 33.27 Billion KRW | 2.87% |
| 2020 Q2 | 35.21 Billion KRW | 9.6% |
| 2020 Q3 | 32.34 Billion KRW | -8.16% |
| 2020 FY | 132.96 Billion KRW | -1.25% |
| 2019 Q3 | 35.05 Billion KRW | -0.53% |
| 2019 FY | 134.64 Billion KRW | 2.95% |
| 2019 Q2 | 35.24 Billion KRW | 7.58% |
| 2019 Q4 | 31.59 Billion KRW | -9.86% |
| 2019 Q1 | 32.75 Billion KRW | 10.03% |
| 2018 Q1 | 31.7 Billion KRW | -2.85% |
| 2018 Q2 | 35.42 Billion KRW | 11.73% |
| 2018 Q3 | 33.88 Billion KRW | -4.35% |
| 2018 FY | 130.79 Billion KRW | 0.24% |
| 2018 Q4 | 29.77 Billion KRW | -12.14% |
| 2017 FY | 130.48 Billion KRW | 8.71% |
| 2017 Q4 | 32.63 Billion KRW | 2.49% |
| 2017 Q3 | 31.84 Billion KRW | -9.23% |
| 2017 Q2 | 35.08 Billion KRW | 13.49% |
| 2017 Q1 | 30.91 Billion KRW | 3.01% |
| 2016 Q1 | 27.73 Billion KRW | 2.37% |
| 2016 Q2 | 32.6 Billion KRW | 17.58% |
| 2016 Q4 | 30 Billion KRW | 1.14% |
| 2016 Q3 | 29.67 Billion KRW | -9.01% |
| 2016 FY | 120.02 Billion KRW | 9.28% |
| 2015 Q1 | 25.72 Billion KRW | -2.38% |
| 2015 FY | 109.82 Billion KRW | 1.85% |
| 2015 Q4 | 27.09 Billion KRW | -2.65% |
| 2015 Q3 | 27.82 Billion KRW | -4.67% |
| 2015 Q2 | 29.19 Billion KRW | 13.48% |
| 2014 Q2 | 28.9 Billion KRW | 12.95% |
| 2014 Q1 | 25.59 Billion KRW | 0.3% |
| 2014 Q4 | 26.35 Billion KRW | -2.36% |
| 2014 FY | 107.83 Billion KRW | -0.28% |
| 2014 Q3 | 26.98 Billion KRW | -6.64% |
| 2013 Q1 | 25.84 Billion KRW | 6.37% |
| 2013 Q2 | 28.47 Billion KRW | 10.19% |
| 2013 Q3 | 28.29 Billion KRW | -0.64% |
| 2013 Q4 | 25.51 Billion KRW | -9.84% |
| 2013 FY | 108.13 Billion KRW | 5.75% |
| 2012 Q3 | 26.26 Billion KRW | 4.87% |
| 2012 FY | 102.25 Billion KRW | -9.55% |
| 2012 Q1 | 26.39 Billion KRW | -18.45% |
| 2012 Q2 | 25.04 Billion KRW | -5.12% |
| 2012 Q4 | 24.29 Billion KRW | -7.5% |
| 2011 FY | 113.04 Billion KRW | 1.06% |
| 2011 Q1 | 25.49 Billion KRW | -2.6% |
| 2011 Q2 | 26.93 Billion KRW | 5.65% |
| 2011 Q3 | 28.24 Billion KRW | 4.86% |
| 2011 Q4 | 32.36 Billion KRW | 14.6% |
| 2010 Q3 | 29.08 Billion KRW | -7.09% |
| 2010 Q1 | 25.29 Billion KRW | -15.37% |
| 2010 Q4 | 26.17 Billion KRW | -10.0% |
| 2010 FY | 111.86 Billion KRW | -8.97% |
| 2010 Q2 | 31.3 Billion KRW | 23.76% |
| 2009 FY | 122.87 Billion KRW | 1.96% |
| 2009 Q4 | 29.88 Billion KRW | -7.53% |
| 2009 Q3 | 32.32 Billion KRW | -8.98% |
| 2009 Q2 | 35.5 Billion KRW | 41.14% |
| 2009 Q1 | 25.15 Billion KRW | -22.67% |
| 2008 Q3 | 27.68 Billion KRW | -15.18% |
| 2008 Q4 | 32.53 Billion KRW | 17.54% |
| 2008 Q2 | 32.63 Billion KRW | 17.94% |
| 2008 Q1 | 27.67 Billion KRW | -9.46% |
| 2008 FY | 120.52 Billion KRW | 7.93% |
| 2007 Q2 | 30.86 Billion KRW | 29.89% |
| 2007 FY | 111.66 Billion KRW | 0.0% |
| 2007 Q3 | 26.47 Billion KRW | -14.21% |
| 2007 Q4 | 30.56 Billion KRW | 15.43% |
| 2007 Q1 | 23.76 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -31.742% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 84.032% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 71.687% |
| HANDOK Inc. | 522.74 Billion KRW | 65.42% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -33.53% |
| Yuhan Corporation | 1858.98 Billion KRW | 90.276% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 72.776% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -247.921% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 87.875% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -33.988% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 51.216% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -104.036% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -6.602% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 19.467% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -31.742% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -131.589% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -19.654% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -106.908% |
| JW Holdings Corporation | 928.07 Billion KRW | 80.523% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 69.911% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 89.172% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 75.851% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 9.722% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 7.937% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 75.115% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -31.742% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 88.064% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 86.857% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 75.851% |
| Yuhan Corporation | 1858.98 Billion KRW | 90.276% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 77.254% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 23.048% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 69.598% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 75.851% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 38.122% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 35.197% |
| CKD Bio Corp. | 160.35 Billion KRW | -12.728% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 65.697% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 49.942% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 21.542% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 9.722% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 79.454% |
| Boryung Corporation | 859.62 Billion KRW | 78.972% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -43.544% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 51.216% |
| JW Lifescience Corporation | 206.86 Billion KRW | 12.616% |